inobrodib

News

CellCentric has raised $220 million in a Series D financing that will help fund pivotal trials of p300/CBP inhibitor inobrodib in multiple myeloma.

News

Pharmacy now represents 25% of employer healthcare spending, and employers are turning to DTC models and nontraditional PBMs to cut costs.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.